CRISPR Therapeutics AG (CRSP) Accounts Payables (2015 - 2026)
CRISPR Therapeutics AG (CRSP) posted Accounts Payables of $13.6 million for Q1 2026, up 22.53% sequentially from $11.1 million in Q4 2025, and up 4.46% YoY from $13.1 million in Q1 2025.
CRISPR Therapeutics AG (CRSP) Accounts Payables (2015 - 2026) Analysis & Trends
CRISPR Therapeutics AG has reported Accounts Payables for 12 years, with the latest figure at $13.6 million in Q1 2026.
- Quarterly Accounts Payables rose 4.46% year-over-year to $13.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.6 million (up 4.46% YoY) and the FY2025 annual result came in at $11.1 million, down 24.28% from the prior year.
- Accounts Payables grew to $13.6 million in Q1 2026 per CRSP's latest filing, from $11.1 million in the prior quarter.
- Over five years, Accounts Payables peaked at $45.2 million in Q1 2023 and troughed at $9.5 million in Q2 2024.
- A 5-year average of $21.4 million and a median of $16.5 million in 2024 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2022 and 2024: Accounts Payables jumped 215.87% in 2022, then plunged 65.74% in 2024.
- Over 5 years, Accounts Payables stood at $27.4 million in 2022, then soared by 39.08% to $38.1 million in 2023, then plunged by 61.44% to $14.7 million in 2024, then declined by 24.28% to $11.1 million in 2025, then advanced by 22.53% to $13.6 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $13.6 million, $11.1 million, and $11.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | 11.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.31 Mn |
| Mar 31, 2026 | 13.65 Mn |
| Dec 31, 2025 | 11.14 Mn |
| Sep 30, 2025 | 11.80 Mn |
| Jun 30, 2025 | 9.75 Mn |
| Mar 31, 2025 | 13.06 Mn |
| Dec 31, 2024 | 14.71 Mn |
| Sep 30, 2024 | 15.58 Mn |
| Jun 30, 2024 | 9.45 Mn |
| Mar 31, 2024 | 16.46 Mn |
| Dec 31, 2023 | 38.15 Mn |
| Sep 30, 2023 | 26.15 Mn |
| Jun 30, 2023 | 27.59 Mn |
| Mar 31, 2023 | 45.15 Mn |
| Dec 31, 2022 | 27.43 Mn |
| Sep 30, 2022 | 32.11 Mn |
| Jun 30, 2022 | 25.24 Mn |
| Mar 31, 2022 | 27.11 Mn |
| Dec 31, 2021 | 14.82 Mn |
| Sep 30, 2021 | 10.17 Mn |